IDH1 mutations may predict higher risk of relapse and shorter survival in the subset of CN-AML patients with mutated NPM1 and absence of FLT3-ITD (molecular low-risk group) (Marcucci et al., 2010; Paschka et al., 2010). The gene discussed is IDH1; the disease is acute myeloid leukemia.